Product Overview
This is the long-acting half of the CJC-1295 family, sold by Generic Peptides in 2 mg, 5 mg and 10 mg freeze-dried vials. What separates it from the short version is a drug affinity complex, a small anchor that lets the peptide ride on circulating albumin. A 30 amino acid tetrasubstituted GHRH analogue with that anchor behaves very differently from the same sequence without it: instead of a pulse it produces a plateau.
The clinical program behind it was real and is the reason the pharmacokinetics are well described. A single subcutaneous injection raised plasma growth hormone 2-10 times above baseline for six days or longer, and IGF-1 climbed 0.5-3 times within 9-11 days, with repeated dosing keeping the level up for as long as 28 days. Half-life estimates in review work land between 5.8 and 8.1 days, so the range is quoted rather than an average.
The same program also ended, and that matters more than the numbers. Development for lipodystrophy and growth hormone deficiency reached phase II and stopped in 2006 after a participant death, so there is no approved dose and no approved form. Because a long-acting secretagogue is judged next to a pulsatile one, the useful comparison in the catalogue is CJC-1295 no DAC, and the finished hormone sits further along the same axis as Somatropin.
Dosage Protocol
Because release runs in days rather than hours, frequency is the main variable and single-dose size matters far less. The figures below come from the clinical program and from vendor arithmetic, not from an approved label.
| Item | Figure | Comment |
| Half-life | 5.8-8.1 days | Subcutaneous route; the albumin anchor is responsible |
| Frequency in descriptions | Once or twice weekly | Rare injections follow directly from the half-life; no single protocol is agreed |
| Growth hormone response | 2-10 times baseline | Held for six days and longer after one dose in the clinical work |
| IGF-1 response | 0.5-3 times higher | Peak within 9-11 days, still raised at 28 days with repeat dosing |
| Female | - | No female schedule is confirmed in the sources |
Reconstitution sets the concentration for whichever vial is on the bench. Mixing 2 ml into the 5 mg vial leaves 2.5 mg per millilitre, so a tenth of a millilitre holds 250 micrograms; the same 2 ml in the 10 mg vial doubles the strength to 5 mg per millilitre, or 500 micrograms per 0.1 ml; and the 2 mg vial with 1 ml sits at 2 mg per millilitre, which is 200 micrograms in that volume. Add the water down the side of the vial and swirl, because shaking damages peptides.
Suggested Protocols
Secretagogues are described in pairs for a simple reason: growth hormone releasing hormone and ghrelin act on different receptors, so combining them is a way of pulling two levers at once. None of the arrangements below has been run through a controlled human study.
Where a shorter pulse is wanted instead of a plateau, Hexarelin belongs to the ghrelin side of the same discussion. Anyone chasing the hormone itself rather than its release should look one step downstream, where Somatropin supplies the finished molecule directly.
What to Expect
- Days, not hours. One shot keeps growth hormone elevated for six days and longer, which is the entire reason injections are weekly.
- IGF-1 lags behind. The rise takes 9-11 days to peak, and repeat doses can hold it up for 28 days, so bloodwork tracks slowly.
- Class-level complaints first. Fluid retention, joint aches, injection site reactions and changing glucose tolerance are the expected early signals.
- Skin, sleep and recovery before strength. In research accounts those are the first things noticed, and visible change takes weeks.
- Long tail after stopping. Because the anchor works through albumin, the effect does not end on the day of the last injection.
- No approved reference point. There is no approved form and no approved dose, and the development program was halted in 2006.
- Testing. Growth hormone releasing factors sit in WADA class S2 and are prohibited at all times, in and out of competition.
Side Effects and Management
Most entries are class effects of growth hormone secretagogues, and the sources do not offer a separate frequency table for this peptide. Anything below is therefore a class-level observation.
Post-Cycle Therapy and Follow-Up
This peptide does not suppress the gonadal axis, so a SERM-based recovery protocol is not part of the picture. Because it works through the body's own pituitary signalling, the sensible end of a block is a taper of frequency and a set of checks.
Storage is ordinary peptide housekeeping: keep the powder cold and protected from light, use a mixed vial within a month of mixing and keep it refrigerated, and never put it in the freezer. With vials as large as 10 mg and injections as rare as weekly, an unused mixed solution is the most likely thing to be wasted.
